Klinefelter syndrome is a genetic condition characterized by the presence of an extra X chromosome in males (XXY instead of the typical XY). While there is no cure for Klinefelter syndrome, treatment focuses on managing associated symptoms and addressing specific needs related to physical, hormonal, and psychosocial aspects. Companies involved in Klinefelter syndrome treatment may contribute to various aspects of patient care.
Clarus Therapeutics Positive Phase III ROMEO-2 trial results demonstrating the long-term safety and efficacy of Jatenzo (testosterone undecanoate) in improving hypogonadism symptoms in Klinefelter Syndrome patients.
AndroGel (Mallinckrodt Pharmaceuticals) FDA approval for a generic version of Testosterone Gel 1.62%, offering a more affordable alternative for testosterone replacement therapy in Klinefelter Syndrome patients.
RegeneXbio Early-stage clinical trial initiated for RGX-314, a potential gene therapy candidate for treating the underlying cause of Klinefelter Syndrome.
Endocrinologics Collaboration with the University of California, San Diego to develop a new therapeutic agent for treating infertility in men with Klinefelter Syndrome.
List of Klinefelter Syndrome Treatment Key Companies in the Market
Klinefelter Syndrome Treatment Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)